Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Preclinical Trial-on-Chip driven CAR-T Infiltration & Trafficking Analysis Service

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

Current CAR-T therapies for hematological malignancies face critical translational challenges, including unpredictable tumor infiltration, inefficient bone marrow homing, and complex stromal resistance, leading to high clinical attrition rates. Creative Biolabs' Preclinical Trial-on-Chip driven CAR-T Infiltration & Trafficking Analysis Service addresses this by offering a transformative, physiologically relevant evaluation platform. We deploy proprietary, immunocompetent "Tumor/Bone Marrow-on-a-Chip" systems that recapitulate the human vascularized niche and dynamic cellular interactions. This enables high-resolution, quantitative analysis of the entire multi-step CAR-T journey, from vascular margination and extravasation to interstitial migration and final tumor engagement, delivering predictive, human-relevant data to de-risk candidate selection and accelerate therapeutic development.

Introduction

The efficacy of chimeric antigen receptor (CAR) T and NK cell therapies against solid tumors remains limited by a multifaceted challenge: insufficient infiltration and suboptimal activation within the tumor microenvironment (TME). This primary obstacle stems from complex physical and biological barriers, including dense stroma, aberrant vasculature, suppressive immune cell populations, and chemokine receptor mismatches, that restrict lymphocyte trafficking, survival, and effector function at the tumor site.

Fig.1 Overcoming stromal resistance: approaches to enhance CAR T/NK cell penetration and activity in solid cancers. (OA Literature) Fig.1 Targeting solid tumor stromal barriers to optimize CAR T/NK cell infiltration and function.¹

Preclinical Trial-on-Chip driven CAR-T Infiltration & Trafficking Analysis Service at Creative Biolabs

Creative Biolabs offers a holistic platform for assessing CAR-T cell functionality in a human-relevant physiological context. Moving beyond conventional 2D methods, our service captures and quantifies the complete cellular journey from migration to cytotoxicity. This enables the validation of critical migratory and infiltrative capacities required for therapeutic candidates to effectively target and engage shielded tumor populations.

What We Can Offer

Our service suite provides a comprehensive and physiologically relevant platform to deconstruct the multi-step journey of CAR-T cells from the vasculature to the tumor core. We offer the following integrated analyses:

Featured services of preclinical trial-on-chip driven CAR-T infiltration & trafficking analysis at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Cryopreserved CAR-T cell batches or viral vector constructs. CAR-T Product: Cryopreserved or fresh engineered T-cells.
Target Cell Lines/Patient Samples: Specific leukemia or lymphoma cell lines or patient-derived primary blasts.
Baseline Data: Existing in vitro cytotoxicity or flow cytometry profiles to establish benchmark performance.

Key Steps:

Workflow of preclinical trial-on-chip driven CAR-T infiltration & trafficking analysis at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

High-Definition Video Data: Time-lapse footage showing CAR-T infiltration and cytotoxic engagement.
Quantitative Trafficking Report: Statistical analysis of extravasation efficiency, mean velocity, and infiltration depth.

Key Advantages

Tailored Microenvironment Modeling: We customize bone marrow niche architectures, including specific anatomical zones, to model the physiological context of your target hematological malignancy.
Flexible High-Throughput Platform: Our system scales to support parallel testing of multiple CAR designs, from initial concept validation to systematic candidate screening.
Quality-by-Design & Aseptic Assurance: Our workflow integrates QbD principles and stringent aseptic controls from chip fabrication to assay execution, ensuring data reliability and regulatory compliance.

FAQs

Q1: How does the chip simulate the "trafficking" of T-cells from the blood?

A1: Our platform includes an engineered endothelial layer under active fluidic flow. This allows us to observe how CAR-T cells adhere to the vessel wall and squeeze through into the bone marrow tissue, mimicking the natural homing process.

Q2: Can we use our own patient-derived cells in your system?

A2: Yes, we encourage the use of patient-derived blasts and stromal cells to create a "personalized" trial-on-a-chip, providing the most accurate prediction of how a specific patient population might respond.

Why Choose Us?

Choose our service for the industry's most advanced validation platform. We uniquely replicate the complex vascular and tri-zonal bone marrow niche to model extrinsic resistance, capturing critical biology missed by animal models. Our predictive, human-relevant data robustly supports your regulatory strategy and de-risks clinical translation.

Customer Reviews

"Using Creative Biolabs' Preclinical Trial-on-Chip in our research has significantly improved our ability to predict which CAR constructs can actually penetrate the bone marrow stroma. The real-time imaging of T-cell extravasation provided far more detail than our previous terminal mouse assays."

— Dr. Jn Sth*.

"Using Creative Biolabs' analysis service has facilitated a deeper understanding of how our CAR-T cells interact with the endogenous immune system. Seeing the upregulation of HLA-DR on non-target cells within the chip gave us the first clear evidence of our product's systemic potential."

— Prof. La M***z.

"Facilitating the transition from 2D to 3D was seamless. Using the trafficking analysis in our research has significantly facilitated the optimization of our media formulations, showing us exactly how different cytokines impact the T-cell "patrolling" velocity in a human niche."

— Dr. Kt Wg*.

How to Contact Us?

Move beyond animal models and gain predictive, human-centric insights into CAR-T cell trafficking and infiltration. Our expert team is ready to tailor a study to validate your lead candidate and de-risk your program. Contact us today for a detailed project consultation and quote to accelerate your therapy's path to the clinic.

Reference

White, Lydia G et al. "Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours." Cancers vol. 14,4 978. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers14040978.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.